Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Molecular, clinical and prognostic characterization of double KRAS/PIK3CA (dKP) mutated metastatic colorectal cancer (mCRC)

Date

08 Oct 2016

Session

Poster Display

Presenters

Julieta Grasselli

Citation

Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370

Authors

J. Grasselli1, E. Elez1, G. Argiles Martinez1, E. Sanz-Garcia1, T. Macarulla1, J. Capdevila1, M. Alsina1, T. Sauri1, C. Hierro1, H. Verdaguer1, I. Matos1, A. Garcia1, P. Nuciforo1, S. Landolfi1, H. Garcia Palmer1, R. Dienstmann2, A. Vivancos3, J. Tabernero1

Author affiliations

  • 1 Medical Oncology, Vall d`Hebron University Hospital Institut d'Oncologia, 08015 - Barcelona/ES
  • 2 Oncology Data Science, Vall d`Hebron University Hospital Institut d'Oncologia, 08035 - Barcelona/ES
  • 3 Genomics, Vall d`Hebron University Hospital Institut d'Oncologia, 08015 - Barcelona/ES
More

Resources

Background

Molecular screening in mCRC has demonstrated an impact in treatment selection and outcome estimation. KRAS mutations (mut) frequently coexist with PIK3CA mut. Molecular, clinical and prognostic association of the dKP group has not been studied in detail.

Methods

657 mCRC patient records that were eligible for targeted mut profile were reviewed. From Jan 2010 – Jun 2014, mass spectrometry (Sequenom oncogene panel) was performed in 497 samples, and from Jul 2014 – Jul 2015, next generation sequencing (MiSeq amplicon oncogene and tumor suppressors panel) in 160.

Results

dKP mut were found in 82 cases (12.5%), RAS/BRAF/PIK3CA wild type (wt) in 38.4%, RAS mut/PIK3CA wt 38.5%, RAS/BRAF wt/PIK3CA mut 3.4% and BRAF mut 7.2%. PIK3CA mut are enriched in KRAS mut as compared to RAS wt (25% vs. 9%, OR = 3.4, p 

Conclusions

The molecular features of dKP samples such as enrichment in particular KRAS/PIK3CA codons, less co-existing TP53 mut, together with their particular clinical characteristics suggest that the biology of these tumors is different from other genomically-defined groups. Nevertheless, co-occurrence of a PIK3CA mut on top of RAS mut does not significantly impact survival in the metastatic setting.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

VHIO

Disclosure

J. Tabernero: Consultant/Advisory role: Amgen, Bayer, Boehringer Ingelheim, Celgene, Chugai, Lilly, MSD, Merck Serono, Novartis, Roche, Sanofi, Symphogen, Takeda, Taiho. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings